AASLD 2023 Practice Guidance on the Clinical Assessment and Management of MASLD (with November 2025 Semaglutide Update)
Adopts the MASLD/MASH nomenclature, formalizes a non-invasive staging pathway anchored on FIB-4 and elastography, and — via the November 2025 AASLD practice update — adds semaglutide as a recommended pharmacotherapy for adults with MASH and F2–F3 fibrosis.
What changed in this edition
- Adoption of the MASLD/MASH nomenclature (NAFLD/NASH terminology retired); MetALD category introduced for metabolic dysfunction plus moderate alcohol.
- Two-step non-invasive pathway: FIB-4 first, then VCTE, MRE, or ELF; biopsy reserved for discordant results or therapy decisions.
- November 2025 update: semaglutide recommended for adults with MASH and F2–F3 fibrosis identified by NITs (VCTE 8–15 kPa, MRE 3.1–4.4 kPa, or ELF 9.2–10.5).
- Lifestyle modification (weight loss, Mediterranean-style diet, physical activity) remains foundational; semaglutide is an adjunct.
- Screening recommended in T2D, obesity with metabolic risk, or persistently elevated aminotransferases.
- HCC surveillance in MASLD cirrhosis every 6 months with US ± AFP; MRI if US inadequate.
- No AASLD recommendation on combining semaglutide with resmetirom given the absence of clinical trial data.
Clinical takeaways
Who to screen
Screen adults with T2D, obesity plus ≥1 metabolic risk factor, or persistently elevated ALT. Start with FIB-4; if indeterminate (1.3–2.67) or high, obtain elastography.
Staging without biopsy
VCTE <8 kPa effectively rules out advanced fibrosis; ≥12 kPa suggests F3–F4. MRE is more accurate when available. Reserve biopsy for discordant results or therapy decisions.
Pharmacologic therapy
Per the November 2025 AASLD update, semaglutide 2.4 mg weekly is recommended for MASH with F2–F3 fibrosis identified by NITs. Resmetirom (FDA-approved March 2024) is a separate option for biopsy- or imaging-confirmed MASH with moderate-to-advanced fibrosis. AASLD does not currently recommend combination therapy.
Metabolic bundle
All MASH patients: structured weight loss (target 7–10%), Mediterranean diet, 150 min/week activity, glycemic and BP optimization, statin when indicated (safe in MASLD), alcohol minimization.
Cirrhosis monitoring
US every 6 months, endoscopic variceal screening, and vaccination per standard cirrhosis care. Transplant evaluation at MELD ≥15 or complications.
Supporting trials
- MAESTRO-NASHPubMed 38324483
Resmetirom achieved MASH resolution and fibrosis improvement at 52 weeks vs placebo.
- ESSENCEPubMed 40305708
Semaglutide 2.4 mg produced MASH resolution without worsening fibrosis in 62.9% vs 34.3% placebo at 72 weeks.
- SYNERGY-NASHPubMed 38856224
Tirzepatide improved MASH histology at all dose levels in biopsy-confirmed disease.
- REGENERATE (Interim)PubMed 31813633
Obeticholic acid showed fibrosis improvement but regulatory concerns limited adoption.
Related reading
MASH (Metabolic-Associated Steatohepatitis): The New Treatment Landscape
With resmetirom (Rezdiffra) becoming the first FDA-approved therapy for MASH in 2024, the treatment paradigm has shifted fundamentally. This guide covers the evidence, patient selection, and the pipeline of emerging therapies for gastroenterologists and hepatologists.
Evidence-Based MedicineType 2 Diabetes Management 2026: ADA Standards of Care Updates
The 2026 ADA Standards of Care introduce updated guidance on GLP-1 agonist and GLP-1/GIP dual agonist positioning, cardiovascular risk reduction, and technology-assisted management. Key changes for primary care and endocrinology practice.